# GoodRx Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/GoodRx Holdings, Inc.). ## Overview GoodRx Holdings, Inc. operates a consumer healthcare platform that helps Americans compare prescription prices, access discount pricing, and manage medication affordability. The company monetizes traffic through prescription transaction fees, subscription offerings, and pharma manufacturer solutions, while also expanding into telehealth and other healthcare services. ## Products & services • Prescription price comparison and GoodRx codes • Prescription transactions and cash network savings • GoodRx Gold and other subscription plans • Pharma manufacturer solutions • Telehealth services and wellness content • Integrated savings programs with PBMs and pharmacies - **Prescription transactions** (72%) — Consumer prescription pricing, discount codes, and transaction-based savings at pharmacies. - **Subscription services** (10%) — Paid consumer plans such as GoodRx Gold that provide enhanced medication savings. - **Pharma manufacturer solutions** (18%) — Commercial services for drug makers, including patient access and affordability programs. - Prescription price comparison and GoodRx codes - Prescription transactions and cash network savings - GoodRx Gold and other subscription plans - Pharma manufacturer solutions - Telehealth services and wellness content - Integrated savings programs with PBMs and pharmacies ## Customers GoodRx sells to consumers seeking lower out-of-pocket prescription costs, but its commercial relationships also span pharmacies, PBMs, and pharmaceutical manufacturers. Consumers use the platform for price transparency and savings, while partners use it to drive volume, improve adherence, and reach patients more efficiently. - **Consumers** (primary) — Individuals using GoodRx to compare prices, access discount codes, and save on prescriptions. - **Pharmacy Benefit Managers (PBMs)** (primary) — PBMs provide cash-network pricing and discounts that GoodRx routes to consumers to generate transactions. - **Retail pharmacies** (primary) — Pharmacies partner with GoodRx to reduce walk-away patients and increase prescription volume. - **Pharmaceutical manufacturers** (secondary) — Drug makers buy access and affordability solutions to support patient uptake and adherence. - **Healthcare providers and telehealth users** (secondary) — Providers and patients use adjacent digital tools and telehealth offerings tied to the platform. - Consumers buying prescriptions who want lower cash prices - Insured and uninsured patients facing high deductibles or copays - Pharmacies that want to reduce abandoned prescriptions - PBMs that want incremental cash-network transaction volume - Pharma manufacturers seeking patient access and affordability programs ## Geography GoodRx generates all of its revenue in the United States, and its platform is built around U.S. prescription pricing, pharmacy networks, and healthcare rules. This makes the business highly exposed to U.S. retail pharmacy dynamics, PBM contracting, and federal and state healthcare policy changes. - **United States** (100%) — All revenue generated in the United States. - All revenue is generated in the United States - Business depends on U.S. pharmacy networks and PBM contracts - Exposure is tied to U.S. healthcare pricing and reimbursement rules - Retail pharmacy store closures can reduce transaction volume - Regulatory changes in U.S. healthcare can affect pricing and demand ## Strategy GoodRx is focused on expanding from prescription savings into a broader consumer healthcare platform while increasing monetization from its existing user base. Management is also emphasizing strategic partnerships, deeper pharmacy relationships, and selective acquisitions to strengthen distribution and improve unit economics. - **Expand multi-product adoption** (medium-term) — Using more offerings per consumer raises lifetime value without proportionate acquisition cost. - **Strengthen partner ecosystem** (medium-term) — PBMs, pharmacies, and manufacturers are core to pricing, traffic, and monetization. - **Grow pharma manufacturer solutions** (short-term) — This segment is growing faster and can diversify revenue away from consumer transaction dependence. - **Improve brand awareness** (long-term) — Awareness is a key barrier to adoption in a consumer healthcare market with many alternatives. - Grow consumer adoption across more GoodRx offerings - Increase monetization from the existing consumer base - Build brand awareness around prescription affordability - Deepen relationships with retail pharmacies - Pursue strategic partnerships, collaborations, and acquisitions ## Risks GoodRx depends on a limited set of PBMs, pharmacies, and transaction-processing vendors, so partner concentration and contract changes can quickly affect pricing and revenue. The company is also exposed to U.S. healthcare regulation, retail pharmacy disruption, and competition for consumer attention, all of which can reduce transaction volume or weaken its value proposition. - **PBM and partner concentration** [high] — A limited number of PBMs generate a significant portion of discounted prices and revenue. - **Retail pharmacy disruption** [high] — Store closures and volume declines reduce prescription transactions processed through the platform. - **U.S. healthcare regulation** [medium] — Federal and state changes to healthcare spending and medication pricing can alter the economics of the platform. - **Competition and consumer awareness** [medium] — The company says awareness is a primary barrier to adoption, so rivals can limit growth. - **Platform and cybersecurity risk** [medium] — The business relies on apps, websites, pricing data, and transaction processing infrastructure. - Revenue depends on a limited number of PBM and pharmacy partners - Retail pharmacy closures can reduce consumer transactions - Healthcare reform and pricing regulation may change demand - Competition can pressure consumer acquisition and brand awareness - Technology and cybersecurity failures could disrupt the platform ## Accounting GoodRx’s revenue is driven by multiple streams, including transaction-based fees, subscriptions, and pharma manufacturer solutions, so mix shifts can materially change reported growth rates. The company also highlights acquisition accounting, software development costs, stock repurchases, and debt refinancing, which affect cash flow presentation and comparability across periods. - **Revenue recognition by stream** — Prescription transactions, subscriptions, and pharma manufacturer solutions - **Subscription churn and plan sunsets** — GoodRx Gold and other subscription offerings - **Business combination accounting** — VCRx acquisition and future strategic acquisitions - **Capitalized software development** — Product development and technology spending - **Debt and restricted net assets** — Parent company liquidity and capital allocation - Revenue mix shifts between transactions, subscriptions, and manufacturer solutions - Subscription counts and plan sunsets affect recurring revenue trends - Acquisition accounting can affect comparability after deals like VCRx - Software development and platform costs influence operating expense timing - Debt refinancing and repurchases affect cash flow and leverage metrics --- *Last updated: 2026-04-28T20:11:51.927733+00:00*